The fund’s objective is to outperform global equity markets over a long-term period (minimum of 5 years) by investing in international equities of companies involved in the medical technology ecosystem, while integrating Environmental, Social and Governance (ESG) criteria in the investment process.
To do so, the management team has split the investment universe into nine categories: noninvasive devices (glasses, hearing aids, etc.), surgery, blood/dialysis, imaging/radiotherapy, cardiology/neurology, medical supplies, diagnosis tools, orthopedics and IT tools and services (softwares, laboratories, etc.).
Within these categories, the eligible investment universe is defined by combining:
- A sustainable approach to exclude the companies with a bad ESG rating (on a global scale or on specific criteria linked to the investment theme) and/or subjected to ESG controversies.
- A fundamental analysis to identify the seemingly most-promising companies on financial criteria or according to their mid-long term outlook.
The about 60 stocks in the final portfolio will be selected on this basis and according to the conviction level of the management team on these stocks.